Business Wire13d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Scholar Rock Names Lisa Wyman As Chief Technical And Quality Officer
Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, ...
3,020 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by KBC Group NV
KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
ETF Daily News26d
Scholar Rock Holding Corporation Furnishes Presentation for J.P. Morgan Healthcare Conference
Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and ...
Yahoo Finance11mon
Scholar Rock Holding Corporation (SRRK)
As of 2:14:50 PM EST. Market Open. CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
Hosted on MSN1mon
SA Asks: Which biotechs are most likely to be acquired near-term?
Sarepta Therapeutics (NASDAQ ... Huntington’s disease candidate advances towards potential FDA approval; Scholar Rock (NASDAQ:SRRK), which has a late-stage spinal muscular atrophy drug and ...
Nasdaq26d
Scholar Rock Holding Reaches Analyst Target Price
In recent trading, shares of Scholar Rock Holding Corp (Symbol: SRRK) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.32/share. When a stock reaches ...
Morningstar13d
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
She joins Scholar Rock’s Executive Team ... she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree ...